Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Danicopan add-on to C5 inhibitor in PNH with EVH (Japan)
jRCT2021210014Phase 3Active, not recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, single-arm trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change in hemoglobin at Week 12. Started Jun 2021; status: active, not recruiting.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2021210014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210014.